New research has been discovered for sure Weight loss drugs It can be associated with increased risk of serious eye conditions, and even vision loss.
How were semaglutide and tilzepatide analysed in two studies published in Jama that included popular drugs such as Ozempic, Wegoby, Munjaro and Zepbound? It affected the health of Americans’ eyes Type 2 diabetes Over two years.
One study found that there is a slight risk of developing non-arterial pre-ischemic ischemic optic neuropathy (NAOIN), a rare eye condition that can lead to sudden loss of vision due to lack of blood flow.
Common weight loss medications can relieve painful arthritis symptoms, doctors report
Of the more than 159,000 study participants with type 2 diabetes, 35 developed Naion compared to 19 in the comparison group.
The Ohio-based researcher also noted an increased risk of developing “other optic neuropathies,” identified in 93 patients.
In the second study, no “statistically significant differences” in Naion in GLP-1 drug users was observed, but there was a slight increase in diabetic retinopathy, an ocular disease that could damage the retina.
Diabetic patients taking GLP-1 may face an increased risk of eye disease, studies suggest
People with type 2 diabetes with GLP-1 showed a slightly increased risk of diabetic retinopathy, but researchers concluded that fewer patients have experienced it Complications that threaten your vision From illness.
“These findings suggest that all patients in type 2 diabetes treated with GLP-1 RAS should be regularly screened and monitored, regardless of existing diabetic retinopathy,” the study authors concluded.
Sue Decotiis, MD, Medical Weight loss doctor New York City said they believe more studies are needed to confirm the association between these drugs and vision loss, as these studies report several conflicting results.
“Nion is a rare condition of the optic nerve and although serious, these studies have not shown to actually increase,” DeCotiis, who was not involved in the study, told Fox News Digital. “It certainly needs more research.”
Diabetics already face high incidence of eye diseases related to blood flow and nerve damage, experts noted.
“Ophthalmologies are often directly related to the degree or lack of diabetes control.”
Click here to sign up for our health newsletter
In most cases, GLP-1 drug Decotiis said it reduces the severity of type 2 diabetes and thus reduces the incidence of eye disease.
These drugs are Cardiovascular diseaselike high blood pressure, and to improve circulation that can improve eye health.
For diabetic patients starting GLP-1, Decotiis recommends scheduling follow-up trials during treatment by ophthalmologists.
“We should take precautions Systematic ophthalmology care For those diabetics with these medications, “But don’t throw your baby out of the bath water.”
Visit us for more health articles www.foxnews.com/health
Novo Nordisk, the manufacturer of Ozempic and Wegovy, provided the following statement when contacted by Fox News Digital:
“Patient safety is Novo Nordisk’s number one priority and we take all reports of adverse events from drug use very seriously. Nion is a very rare eye disease and not a harmful drug reaction to sell approved labels (Ozumpic, Leibels, we are Govy) formulations for sale (Ozumpic, Leibels, we are Govy).”
“Novo Nordisk conducted the analysis via a randomized controlled clinical trial with a GLP-1 receptor agonist, including a blinded ophthalmologist’s assessment to confirm the Naion diagnosis. The current assessment is that these data do not suggest a causal relationship between GLP-1 RA use and Naion events.”
